Biological agents significantly reduce surgery rates in Crohn’s disease

In the era of biological agents, Crohn’s disease patients show varying surgery rates based on Montreal classifications. Notably, type B3 patients have the highest likelihood of requiring surgery, while type A1 patients tend to undergo surgery earlier than A2 and A3. The use of biological agents within one month of diagnosis significantly decreases the chances of surgical intervention, as does receiving treatment within 19 months of symptoms onset. Behavior changes during the disease course indicate poorer surgical outcomes.